Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.

Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.

Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.

Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.

Dr. Botond Roska says we should keep our eyes on gene therapy.

Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.

Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.